AI Policy

    When AI designs a drug, who gets the credit?

    Navigating the legal and ethical gray zones of algorithmic authorship in modern pharmaceutical research.

    When the biotech company Insilico Medicine used its computer models to propose a promising drug for pulmonary fibrosis, it enthusiastically claimed in a press release that the molecule had been “discovered by” its generative AI platform. Insilico leads a pack of companies using A...

    MTR

    MIT Technology Review

    Source

    MIT Technology Review
    When AI designs a drug, who gets the credit?
    AI Analysis

    Generated insight by OnAirToday AI

    The debate over AI-generated drug discovery challenges traditional intellectual property frameworks by blurring the lines between human innovation and machine-assisted output. Establishing clear credit is essential for future patent legitimacy and navigating the legal complexities of algorithmic authorship.

    Powered by AI • Not a substitute for human analysisMore Insights →
    Read the full story at MIT Technology Review →
    Share

    Comments

    Keep comments relevant and respectful. No links, advertising, self-promotion, or spam.

    0/1000